Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis

Infection and Immunity

Volumn 78, Issue 6, 2010, Pages 2466-2476

  Di Bonaventura, Giovanni ^a   Pompilio, Arianna ^a   Zappacosta, Roberta ^a   Petrucci, Francesca ^a   Fiscarelli, Ersilia ^b   Rossi, Cosmo ^a   Piccolomini, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRO ALPHA PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KC PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 5; PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATELECTASIS; BRONCHITIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DBA 2 MOUSE; DISEASE MODEL; FEMALE; LUNG; LUNG ALVEOLITIS; LUNG EDEMA; LUNG HEMORRHAGE; MALE; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PLEURA ADHESION; PLEURA DISEASE; PRIORITY JOURNAL; RESPIRATORY FUNCTION; RESPIRATORY TRACT INFECTION; STENOTROPHOMONAS MALTOPHILIA; WEIGHT REDUCTION;

EID: 77952733658     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01391-09     Document Type: Article

References (56)

1. Armstrong, D. S., K. Grimwood, R. Carzino, J. B. Carlin, A. Olinsky, and P. D. Phelan. 1995. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Br. Med. J. 310:1571-1572.
2. Ballestero, S., I. Virseda, H. Escobar, L. Lucrecia, and F. Baquero. 1995. Stenotrophomonas maltophilia in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 14:728-779.
3. Balough, K., M. McCubbin, M. Weinberger, W. Smits, R. Ahrens, and R. Fick. 1995. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr. Pulmonol. 20:63-70.
4. Barclay, N. G., J. C. Spurrell, T. F. Bruno, D. G. Storey, D. E. Woods, and C. H. Mody. 1999. Pseudomonas aeruginosa exoenzyme S stimulates murine lymphocyte proliferation in vitro. Infect. Immun. 67:4613-4619.
5. Belardelli, F. 1995. Role of interferons and other cytokines in the regulation of the immune response. Acta Pathol. Microbiol. Immunol. Scand. 103:161-179.
6. Bonfield, T. L., J. R. Panuska, M. W. Konstan, K. A. Hillard, J. B. Hillard, H. Ghnaim, and M. Berger. 1995. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 152:2111-2118.
7. Boucher, J. C., H. Yu, M. H. Mudd, and V. Deretic. 1997. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect. Immun. 65:3838-3846.
8. Brennan, S., P. D. Sly, C. L. Gangell, N. Sturges, K. Winfield, M. Wikstrom, S. Gard, J. W. Upham, et al. 2009. Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. Eur. Respir. J. 34:655-661.
9. Burns, J. L., J. Emerson, J. R. Stapp, D. L. Yim, J. Krzewinski, L. Louden, B. W. Ramsey, and C. R. Clausen. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:158-163.
10. Cash, H. A., D. E. Woods, B. McCullough, W. G. Johanson, Jr., and J. A. Bass. 1979. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 119:453-459.
11. Chmiel, J. F., and P. B. Davis. 2003. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir. Res. 4:8.
12. Crossman, L. C., V. C. Gould, J. M. Dow, G. S. Vernikos, A. Okazaki, M. Sebaihia, D. Saunders, C. Arrowsmith, T. Carver, N. Peters, E. Adlem, A. Kerhornou, A. Lord, L. Murphy, K. Seeger, R. Squares, S. Rutter, M. A. Quail, M. A. Rajandream, D. Harris, C. Churcher, S. D. Bentley, J. Parkhill, N. R. Thomson, and M. B. Avison. 2008. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol. 9:R74.
13. Reference deleted.
14. Demko, C. A., R. C. Stern, and C. F. Doershuk. 1998. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr. Pulmonol. 25:304-308.
15. Denton, M. 1997. Stenotrophomonas maltophilia: an emerging problem in cystic fibrosis patients. Rev. Med. Microbiol. 8:15-19.
16. De Rose, V. 2002. Mechanisms and markers of airway inflammation in cystic fibrosis. Eur. Respir. J. 19:333-340.
17. Di Bonaventura, G., A. Pompilio, C. Picciani, M. Nicoletti, R. Zappacosta, and R. Piccolomini. 2008. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia: implications in cystic fibrosis. Clin. Microbiol. Infect. 14(Suppl. 7):S178.
18. Di Bonaventura, G., G. Prosseda, F. Del Chierico, S. Cannavacciuolo, P. Cipriani, A. Petrucca, F. Superti, M. G. Ammendolia, C. Concato, E. Fiscarelli, M. Casalino, R. Piccolomini, M. Nicoletti, and B. Colonna. 2007. Molecular characterization of virulence determinants of Stenotrophomonas maltophilia strains isolated from patients affected by cystic fibrosis. Int. J. Immunopathol. Pharmacol. 20:529-537.
19. Dubin, P. J., and J. K. Kolls. 2007. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:519-528.
20. Elborn, J. S., S. M. Cordon, P. J. Western, I. A. MacDonald, and D. J. Shale. 1993. Tumor necrosis factor-alpha, resting energy expenditure and cachexia in cystic fibrosis. Clin. Sci. (London) 85:563-568.
21. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
22. Gladman, G., P. J. Connor, R. F. Williams, and T. J. David. 1993. Controlled study of Pseudomonas maltophilia in cystic fibrosis. Arch. Dis. Child. 67:192-195.
23. Goldstein, E., E. S. Munson, C. Eagle, R. Martucci, and P. D. Hoeprich. 1970. Influence of anesthetic agents on murine pulmonary bactericidal activity. Antimicrob. Agents Chemother. 10:231-235.
24. Hart, P. H., G. F. Vitti, D. R. Burgess, G. A. Whitty, D. S. Piccoli, and J. Hamilton. 1989. Potential anti-inflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc. Natl. Acad. Sci. U. S. A. 86:3803-3807.
25. Hauser, A. R., E. Cobb, M. Bodi, D. Mariscal, J. Valles, J. N. Engel, and J. Rello. 2002. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 30:521-528.
26. Ionescu, A. A., T. D. Mickleborough, C. E. Bolton, M. R. Lindley, L. S. Nixon, G. Dunseath, S. Luzio, D. R. Owens, and D. J. Shale. 2006. The systemic inflammatory response to exercise in adults with cystic fibrosis. J. Cyst. Fibros. 5:105-112.
27. Johansen, H. K., F. Espersen, S. S. Pedersen, H. P. Hougen, J. Rygaard, and N. Høiby. 1993. Chronic Pseudomonas aeruginosa lung infection in normal and athymic rats. APMIS 101:207-225.
28. Johnston, R. B., Jr. 1993. The complement system in host defense and inflammation: the cutting edges of a double edged sword. Pediatr. Infect. Dis. J. 12:933-941.
29. Jones, A. M., M. E. Dodd, and J. R. Govan. 2004. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 59:948-951.
30. Karpati, F., A. S. Malmborg, H. Alfredsson, L. Hjelte, and B. Strandvik. 1994. Bacterial colonization with Xanthomonas maltophilia: a retrospective study in a cystic fibrosis patient population. Infection 22:258-263.
31. Khan, T. Z., J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, and D. W. H. Riches. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1075-1082.
32. Konstan, M. W., K. A. Hilliard, T. M. Norvell, and M. Berger. 1994. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am. J. Respir. Crit. Care Med. 150:448-454.
33. Kube, D., U. Sontich, D. Fletcher, and P. B. Davis. 2001. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:L493-L502.
34. Lambiase, A., V. Raia, M. Del Pezzo, A. Sepe, V. Carnovale, and F. Rossano. 2006. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect. Dis. 6:4.
35. Landrum, M. L., N. G. Conger, and M. A. Forgione. 2005. Trimethoprim-sulfamethoxazole in the treatment of Stenotrophomonas maltophilia osteomyelitis. Clin. Infect. Dis. 40:1551-1552.
36. Leverkoehne, I., H. Holle, F. Anton, and A. D. Gruber. 2006. Differential expression of calcium-activated chloride channels (CLCA) gene family members in the small intestine of cystic fibrosis mouse models. Histochem. Cell Biol. 126:239-250.
37. Liu, J. H., and J. Y. Djeu. 1995. Role of cytokines in neutrophil functions, p. 71-86. In B. B. Aggarwal and R. K. Puri (ed.), Human cytokines: their role in disease and therapy. Blackwell Science Inc., Cambridge, United Kingdom.
38. Miyairi, I., J. A. Franklin, M. Andreansky, K. M. Knapp, and R. T. Hayden. 2005. Acute necrotizing ulcerative gingivitis and bacteremia caused by Stenotrophomonas maltophilia in an immunocompromised host. Pediatr. Infect. Dis. J. 24:181-183.
39. Morissette, C., C. Francoeur, C. Darmond-Zwaig, and F. Gervais. 1996. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect. Immun. 64:4984-4992.
40. Mulligan, M. S., A. A. Vaporciyan, M. Miyasaka, T. Tamatani, and P. A. Ward. 1993. Tumor necrosis factor regulates in vivo intrapulmonary expression of ICAM-1. Am. J. Pathol. 142:1739-1744.
41. Noah, T. L., H. R. Black, P. W. Cheng, R. E. Wood, and M. W. Leigh. 1997. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J. Infect. Dis. 175:638-647.
42. O'Sullivan, R., S. O. Carrigan, J. S. Marshall, and T. J. Lin. 2008. Signal transducer and activator of transcription 4 (STAT4), but not IL-12 contributes to Pseudomonas aeruginosa-induced lung inflammation in mice. Immunobiology 213:469-479.
43. Ryan, R. P., Y. Fouhy, B. F. Garcia, S. A. Watt, K. Niehaus, L. Yang, T. Tolker-Nielsen, and J. M. Dow. 2008. Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa. Mol. Microbiol. 68:75-86.
44. Schall, T. J. 1994. The chemokines, p. 419-460. In A. W. Thomson (ed.), The cytokine handbook, 2nd ed. Academic Press, San Diego, CA.
45. Speert, D. P., B. Steen, K. Halsey, and E. Kwan. 1999. A murine model for infection with Burkholderia cepacia with sustained persistence in the spleen. Infect. Immun. 67:4027-4032.
46. Spicuzza, L., C. Sciuto, G. Vitaliti, G. Di Dio, S. Leonardi, and M. La Rosa. 2008. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur. J. Clin. Microbiol. Infect. Dis. 28:191-195.
47. Steinkamp, G., B. Wiedemann, E. Rietschel, A. Krahl, J. Gielen, H. Barmeier, and F. Ratjen. 2005. Prospective evaluation of emerging bacteria in cystic fibrosis. J. Cyst. Fibros. 4:41-48.
48. Stotland, P. K., D. Radzioch, and M. M. Stevenson. 2000. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis. Pediatr. Pulmonol. 30:413-420.
49. Talmaciu, I., L. Varlotta, J. Mortensen, and D. V. Schidlow. 2000. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr. Pulmonol. 30:10-15.
50. Tan, K., S. P. Conway, K. G. Brownlee, C. Etherington, and D. G. Peckham. 2002. Alcaligenes infection in cystic fibrosis. Pediatr. Pulmonol. 34:101-104.
51. Van Couwenberghe, C. J., T. B. Farver, and S. H. Cohen. 1997. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect. Control Hosp. Epidemiol. 18:316-321.
52. Villarino, M. E., L. E. Stevens, B. Schable, G. Mayers, J. M. Miller, J. P. Burke, and W. R. Jarvis. 1992. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect. Control Hosp. Epidemiol. 13:201-206.
53. Wainwright, C. E., M. W. France, P. O'Rourke, S. Anuj, T. J. Kidd, M. D. Nissen, T. P. Sloots, C. Coulter, Z. Ristovski, M. Hargreaves, B. R. Rose, C. Harbour, S. C. Bell, and K. P. Fennelly. 2009. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax 64:926-931.
54. Waters, V. J., M. I. Gómez, G. Soong, S. Amin, R. K. Ernst, and A. Prince. 2007. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect. Immun. 75:1698-1703.
55. Wilson, K. R., J. M. Napper, J. Denvir, V. E. Sollars, and H. D. Yu. 2007. Defect in early lung defence against Pseudomonas aeruginosa in mice is associated with acute inflammatory lung injury and reduced bactericidal activity in naive macrophages. Microbiology 153:968-979.
56. Yu, H., S. Z. Nasr, and V. Deretic. 2000. Innate lung defenses and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis. Infect. Immun. 68:2142-2147.